Cargando…

Cost-effectiveness of Human Papillomavirus Vaccination in the United States

We describe a simplified model, based on the current economic and health effects of human papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old girls in the United States. Under base-case parameter values, the estimated cost per quality-adjusted life year gained...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesson, Harrell W., Ekwueme, Donatus U., Saraiya, Mona, Markowitz, Lauri E.
Formato:	Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600200/ https://www.ncbi.nlm.nih.gov/pubmed/18258117 http://dx.doi.org/10.3201/eid1402.070499

Ejemplares similares

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Human Papillomavirus–Attributable Cancers — United States, 2012–2016
por: Senkomago, Virginia, et al.
Publicado: (2019)

Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015
por: Van Dyne, Elizabeth A., et al.
Publicado: (2018)

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
por: Meites, Elissa, et al.
Publicado: (2019)

CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide
por: Senkomago, Virginia, et al.
Publicado: (2017)

Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States
por: Steinau, Martin, et al.
Publicado: (2014)

Human Papillomavirus Prevalence in Invasive Laryngeal Cancer in the United States
por: Hernandez, Brenda Y., et al.
Publicado: (2014)

Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018
por: Rosenblum, Hannah G., et al.
Publicado: (2021)

Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States
por: Stokley, Shannon, et al.
Publicado: (2013)

Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States
por: Stokley, Shannon, et al.
Publicado: (2014)

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States
por: Chesson, Harrell W, et al.
Publicado: (2008)

Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States
por: Meites, Elissa, et al.
Publicado: (2022)

Cancers Associated with Human Papillomavirus in American Indian and Alaska Native Populations — United States, 2013–2017
por: Melkonian, Stephanie C., et al.
Publicado: (2020)

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
por: Kim, Jane J, et al.
Publicado: (2009)

Awareness of breast cancer risk related to a positive family history and alcohol consumption among women aged 15–44 years in United States
por: Khushalani, Jaya S., et al.
Publicado: (2019)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

Medical Costs and Productivity Losses of Cancer Survivors — United States, 2008–2011
por: Ekwueme, Donatus U., et al.
Publicado: (2014)

Cost Analysis of Screening for, Diagnosing, and Staging Prostate Cancer Based on a Systematic Review of Published Studies
por: Ekwueme, Donatus U, et al.
Publicado: (2007)

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
por: Kim, Jane J., et al.
Publicado: (2021)

Costs, Health Benefits, and Cost-Effectiveness of Chlamydia Screening and Partner Notification in the United States, 2000–2019: A Mathematical Modeling Analysis
por: Rönn, Minttu M., et al.
Publicado: (2023)

Cost-effectiveness of human papillomavirus vaccination in Germany
por: Damm, Oliver, et al.
Publicado: (2017)

Cost-effectiveness of Chlamydia Vaccination Programs for Young Women
por: Owusu-Edusei, Kwame, et al.
Publicado: (2015)

Is Health Insurance Literacy Associated With Financial Hardship Among Cancer Survivors? Findings From a National Sample in the United States
por: Zhao, Jingxuan, et al.
Publicado: (2019)

Cost Effectiveness of a Potential Vaccine for Human papillomavirus
por: Sanders, Gillian D., et al.
Publicado: (2003)

Cost-effectiveness of different human papillomavirus vaccines in Singapore
por: Lee, Vernon J, et al.
Publicado: (2011)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator
por: Trogdon, Justin G., et al.
Publicado: (2015)

Costs of delivering human papillomavirus vaccination in Tanzania
por: Struckmann, V, et al.
Publicado: (2022)

Role and uptake of human papillomavirus vaccine in adolescent health in the United States
por: Sudenga, Staci L, et al.
Publicado: (2011)

Factors Associated with Human Papillomavirus Vaccination among Women in the United States
por: Sims, Alexis, et al.
Publicado: (2018)

Factors Affecting Human Papillomavirus Vaccine Trends in the United States of America
por: Vasireddy, Deepa, et al.
Publicado: (2023)

Human Papillomavirus Genotype Prevalence in Invasive Penile Cancers from a Registry-Based United States Population
por: Hernandez, Brenda Y., et al.
Publicado: (2014)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels
por: Jemal, Ahmedin, et al.
Publicado: (2013)

Cost of a human papillomavirus vaccination project, Zimbabwe
por: Hidle, Anna, et al.
Publicado: (2018)

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination
por: Goldhaber-Fiebert, Jeremy D, et al.
Publicado: (2007)

Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States
por: Wheeler, Cosette M., et al.
Publicado: (2009)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003–2010()
por: Petrosky, Emiko Y., et al.
Publicado: (2015)

Economic evaluation of human papillomavirus vaccination in the United Kingdom
por: Jit, Mark, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qljgilcj0l1770udgcub4fuvej